DRUG · Mapped RxNorm record
Interferon alfa-n3
Normalized identity: interferon alfa-n3 View linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Three Preparations of Low-Dose Oral Alpha Interferon in HIV-Infected Patients With CD4+ Counts >= 50 and <= 350 Cells/mm3
NCT00000844
Study summary
ClinicalTrials.govA Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Three Preparations of Low-Dose Oral Alpha Interferon in HIV-Infected Patients With CD4+ Counts >= 50 and <= 350 Cells/mm3
Design: INTERVENTIONAL · Status: COMPLETED · Phase: NA
Loading study purpose, treatment groups and outcomes…
View the complete registry record, eligibility and contacts at ClinicalTrials.gov
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
Interferon alfa-n1
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Advertisement
Conditions
HIV Infectionsunresolved
Interventions
Interferon alfa-n3DRUG · verified · RxNorm: interferon alfa-n3
Sponsors & collaborators
Mapped research locations
Washington D.C.District of Columbia, United States3New YorkNew York, United States2Los AngelesCalifornia, United States1PhiladelphiaPennsylvania, United States1NashvilleTennessee, United States1MinneapolisMinnesota, United States1DetroitMichigan, United States1New HavenConnecticut, United States1BrooklynNew York, United States1WilmingtonDelaware, United States1Redwood CityCalifornia, United States1ValhallaNew York, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00000844 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.